Glucinax^®

GLUCINAX is a metformin medicine indicated for the treatment of type 2 diabetes mellitus, particularly in overweight patients, when dietary management and exercise alone do not result in adequate glycemic control.

GLUCINAX is indicated for the treatment of type 2 diabetes mellitus, particularly in overweight patients, when dietary management and exercise alone do not result in adequate glycemic control. In adults, it may be used as monotherapy or in combination with other oral antidiabetic agents or insulin. A reduction in diabetic complications has been shown in overweight patients treated with metformin as first-line therapy after diet failure.

Metformin is a biguanide with antihyperglycemic effects on basal and post-prandial hyperglycemia. It does not stimulate insulin secretion.

Administer during or after meals. Dose should be individualized according to blood glucose control and tolerability. Assess renal function before treatment initiation and regularly thereafter.

Metformin does not stimulate insulin secretion and therefore does not cause hypoglycemia.

Monitor blood glucose control and adjust treatment under medical supervision according to the patient’s response and renal function.

Metformin is contraindicated in severe renal failure (GFR <30 mL/min). The risk of lactic acidosis increases with acute worsening of renal function, cardiorespiratory illness or sepsis. Use the approved product information for complete warnings.

Each film-coated tablet contains Metformin Hydrochloride BP 1000 mg. Glucinax is available in boxes of 30 or 100 tablets, following the British Pharmacopoeia standard.